GluBio Therapeutics

Biotech & Life Sciences · China · Founded 2021

Engages in molecular glue-targeted protein degradation drug discovery MoreLess

GluBio Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines through targeted protein degradation (TPD). The company operates in the biotechnology sector, primarily serving patients with unmet medical needs across various therapeutic areas. GluBio's proprietary TPD discovery platform and advanced screening capabilities enable the creation of highly selective small molecule degraders. Headquartered in San Diego, CA, with research operations in the United States and China, GluBio leverages its seasoned team of drug developers to advance its diverse pipeline. The business model revolves around the research and development of novel therapies, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, partnerships, and potential licensing agreements. Keywords: targeted protein degradation, small molecule medicines, biopharmaceutical, innovative therapies, drug discovery, clinical trials, biotechnology, therapeutic areas, proprietary platform, selective degraders.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

GluBio Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2021
Headquarters: China
Employees: 12
Open positions: None listed
Dealroom signal: 73.6

Website ↗LinkedIn ↗

client focusb2bsub industryPharmaceuticalsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorMedical ResearchsectorDrug DevelopmentsectorResearch and DevelopmentsectorBiotech and PharmasectorproteomicssectorDT and LSsectorscience-based

Valuation & funding

GluBio Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Feb 2026	$30M	$120M	Sanofi	↗
SERIES AOther financing	Aug 2022	$22M	$88M	Lilly Asia Ventures · Kaitai Capital · Qiming Venture Partners	↗
SERIES AOther financing	Feb 2022	$50M	$200M	Legend Capital · Lilly Asia Ventures · Kaitai Capital · K2VC	↗

Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

GluBio Therapeutics website traffic

Latest recorded traffic for GluBio Therapeutics is 1.1K monthly website visits, up 189.5% over the last three months. GluBio Therapeutics's team grew 9.1% over the past year.

Latest monthly visits1.1K 3-month web change+189.5% 1-year team growth+9.1%

Monthly website visits23 observations · Apr 2023–Jun 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

GluBio Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNxera Pharma UK \| Heptares TherapeuticsDevelops novel, small-molecule drugs for G-protein-coupled receptors	Great Abington, United Kingdom	Acquired	—	$59M	$400M
EBEXO BiologicsNovel nanomedicine platform for rare disease therapeutics	Liège, Belgium	Operational
VTVasa TherapeuticsPrecision medicine for heart failure and healthy aging	Encinitas, United States	Operational
CPConvert PharmaceuticalsHypoxia-activated prodrugs targeting treatment-resistant tumors	Liège, Belgium	Operational
BIBioxodesThrombo-inflammatory therapeutics for intracerebral hemorrhage and stroke	Marche-en-Famenne, Belgium	Operational
BTBooster TherapeuticsBoosting cellular homeostasis to prevent and treat diseases of aging	Berlin, Germany	Operational
CECelltrionGlobal biotech company that launched the world's first monoclonal antibody biosimilar	Incheon, South Korea	Operational
TUTubulisGenerates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology	Planegg, Germany	Acquired

Showing 8 of the closest matchesCompare every metric →

Talent graph

GluBio Therapeutics's talent

Book a demo to see the people

Team profiled 2 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on GluBio Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 7 investors entered at this stage

Legend Capital

Lilly Asia Ventures

Kaitai Capital

K2VC

Qiming Venture Partners

E Fund Management

Sanofi

Global footprint

Where GluBio Therapeutics has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States70%

🇨🇳 China30%

2 countries shown

In the news

Latest news about GluBio Therapeutics

Recent press, funding announcements, and product moves mentioning GluBio Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about GluBio Therapeutics

An AI-synthesized read of the highest-engagement posts about GluBio Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GluBio Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.